Marketing-authorisation holder · United States
Daiichi Sankyo, Inc
6 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
6 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
6 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| DATROWAY100mg · Injectable | Datopotamab deruxtecan | United States | Marketed | 2025 |
| DATROWAY100mg · Injectable | Datopotamab deruxtecan | United States | Marketed | 2025 |
| ENHERTU100mg · Injectable | Fam-trastuzumab deruxtecan | United States | Marketed | 2019 |
| SAVAYSA15mg base | 30mg base | 60mg base · Tablet | Edoxaban | United States | Marketed | 2015 |
| TURALIO125mg base | 200mg base · Capsule | Pexidartinib | United States | Marketed | 2019 |
| VANFLYTA17.7mg base | 26.5mg base · Tablet | Quizartinib | United States | Marketed | 2023 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 6 | 6 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.